Office-use compounding in Alabama

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

Where state permission and federal exemption come apartHigh confidence

This is the clearest place in the corpus to see that they are two different questions. Section 34-23-160 contains no "in accordance with federal law" limb, no cross-reference to the federal compounding provisions and no FDA hook anywhere in its text. So the permission is genuinely effective as Alabama law — a pharmacy relying on it has real state authorisation, not a conduit that hands the question somewhere else. And by the same token it leaves 21 U.S.C. § 353a exactly where it found it: office stock is not compounded for an identified individual patient on receipt of a valid prescription order, so the federal exemptions are not engaged. Both statements are true at the same time, and neither one answers the other.Compare Pennsylvania, which defers to federal law and therefore authorises nothing independently. Alabama refuses to defer and therefore authorises something federal law does not. That is why the honest sentence about this state always names the level of government: "Alabama expressly permits office-use compounding as a matter of state law" is defensible, and dropping the last five words converts it into a federal claim that nothing in Alabama law supports.

The gate is paperwork and destination, not scarcityHigh confidence

Four conditions, all in subsection (a): a prescriber order stating the formula and the quantity is filed at the pharmacy; the product is administered in the prescriber’s office; it is not dispensed to the patient; and a record of the sale to the prescriber stays on file for at least a year, carrying the prescriber’s name and address, the date, and a description and amount of the product. There is no emergency trigger, no commercial-unavailability test, no numeric quantity cap and no board pre-approval.

A mandatory label legend — the only one in this batch that is in forceHigh confidence

Subsection (c) is a single sentence: the label shall include the phrase "For Office Use". Subsection (b) sets the rest of the label — the designated name and strength of the finished product, the quantity, the date compounded, the beyond use date, a lot or batch number, anything else the pharmacist deems necessary, and the pharmacy’s name and address.

The outer bound is qualitative and nobody has defined itHigh confidence

Section 34-23-150(5) treats the distribution of "inordinate amounts" of compounded products without a prescriber/patient/pharmacist relationship as manufacturing, and the companion term at § 34-23-150(7) defines reasonable amounts in inventory as "the amount that is required to meet historical dispensing needs". "Inordinate" is undefined in the statute, in the board’s rules and in every guidance document checked.This is the only ceiling on the permission, which makes it the provision a board would reach for against an office-stock programme run at scale. A practice cannot compute its compliance with it in advance.

Sterile and non-sterile — the split sits one level upHigh confidence

Section 34-23-160 makes no distinction between them. The distinction attaches instead to the pharmacy’s own credential: Ala. Admin. Code r. 680-X-2-.19 requires a pharmacy compounding sterile preparations to be certified as a parenteral sterile compounding pharmacy by the Alabama State Board of Pharmacy, with an additional four-hour board-approved programme for pharmacists compounding sterile products from non-sterile components.

The board has never written an implementing rule, and that is a findingHigh confidence

The phrases "office use", "office stock" and "not for resale" return no hits across the board’s administrative code. The board holds express rulemaking authority at § 34-23-162 and has not used it here. Its only compounding rule is 680-X-2-.43 in its entirety, which requires pharmacies that compound to follow the applicable current chapters of the United States Pharmacopeia–National Formulary. Alabama office use is governed by statute alone, with USP as the quality overlay.A board that governs by statute alone often governs in practice by newsletter, and no newsletter sweep was performed. Treat the silence in the rules as an absence of published rulemaking rather than as an absence of board position.

Veterinary supply rides the same ruleHigh confidence

There is no separate veterinary limb. Section 34-23-161 provides that drugs for animals may be compounded on an order or prescription, and that prescriptions for animals are handled and filled in the same manner as prescriptions for humans. Alabama is the only state reviewed here where the human channel is not the narrower of the two.

Alabama has no percentage clause, and does not need oneHigh confidence

Searches for "five percent", "5 percent" and "5%" return nothing across the chapter and the board’s code. The analogue is qualitative: § 34-23-1(31) exempts the sale, purchase or trade of a drug by a retail pharmacy to another retail pharmacy or practitioner "for relief of temporary shortages" from the definition of wholesale distribution. That is an exemption from distributor licensure only, it is triggered by scarcity, and a routine office-use programme fails it.Which does not matter, because § 34-23-160 authorises the supply directly and has no scarcity predicate. Reaching Alabama’s right answer through the shortage exemption imports a gate the governing section does not contain — right answer, wrong route, and the wrong route is the publishable error. Note separately that the board’s rule-level mirror at 680-X-2-.23(1)(e) carries a limb the statute lacks, for transfers pursuant to a prescription; § 34-23-92.1(c) allows a rule to supplement a statutory definition but not to conflict with a statute.

Entity or person — and the ownership-blind clause cuts the way nobody expectsHigh confidence

Authority attaches to a named individual and no entity credential exists for a practice to obtain. Section 34-23-11(a) turns on a practitioner "personally" compounding, dispensing, administering or supplying to "his or her" patient; § 34-23-32(f) names "a duly licensed doctor" as the lawful recipient; the controlled-substance rule issues to "every physician". Alabama demonstrably knows how to write an entity credential and wrote one for pharmacies instead — § 34-23-30(b)(3) provides that where the pharmacy is owned by a corporation, the permit issues in the corporation’s name.Rule 540-X-4-.05(5) is the clause most likely to be misread. It applies the registration duty to physicians without respect to whether the controlled substances were purchased by an individual physician, a professional association or corporation, a for-profit or not-for-profit corporation, a hospital, clinic or other medical facility. That cuts AGAINST entity possession rather than for it: it makes ownership of the stock legally irrelevant and pins the duty on the physician regardless of who bought it. It is an anti-laundering clause, not an entity authorisation, and reading it as the latter has it exactly backwards.

Last change, and one already scheduledHigh confidence

Section 34-23-160 has not been amended since Act 2017-422; its history line runs "Act 2003-389, p. 1094, §11; Act 2017-422, §1." Alabama’s 2026 session adjourned sine die on 9 April 2026 and bills do not carry over, so the next legislative opportunity is February 2027.A new board rule, 680-X-A, takes effect 15 October 2026 and attaches dollar penalties to this section for the first time — compounding without a prescriber order and labelling non-compliance each carry ranges up to $3,000, with far larger ranges for failing to meet USP standards and for uncertified sterile compounding. The comment period has closed. It changes the consequences of getting § 34-23-160 wrong, not the rule itself.

Alabama at a glance

Receiving 503B office stock in Alabama

Alabama licenses outsourcing facilities through the Board of Pharmacy under an express category, exempts the physician practice from permitting by name, and then puts the controlled-substance credential somewhere no compliance matrix expects: the practitioner’s own licensing board.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Alabama asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

A permit from the Alabama State Board of Pharmacy. Section 34-23-32(g) bars any manufacturer, repackager, third-party logistics provider, wholesale drug distributor, private label distributor, outsourcing facility or pharmacy business in a legend drug’s supply chain from shipping into the state without a valid board permit, and sets a civil penalty of $4,000 for each violation. The board’s fee schedule carries the category literally as "503-B Outsourcers" at $750 initial and $500 annual renewal. There is no separate non-resident class.Two burdens fall on an out-of-state facility and the first is unusual: rule 680-X-2-.23(9)(b) requires an outsourcing facility to have an Alabama-licensed supervising pharmacist for the individual location — at its own site, not in Alabama. Out-of-state inspections may be contracted to another board or to NABP at the permit holder’s cost. A fee trap for anyone building a chart: the fee was raised effective 13 April 2026 and reverted to $750/$500 effective 14 June 2026 when a later amendment drafted against the pre-increase text wiped out the increase as a side effect. Do not cite the April–June window.

Does your practice need a permit?High confidence

No, and Alabama says so twice. Section 34-23-32(c) exempts the professional practice of any physician licensed to practice medicine from the requirements of that section, and § 34-23-11(a) provides that nothing in the chapter prevents a licensed practitioner of the healing arts from personally compounding, dispensing, administering or supplying drugs to his or her patient.The supplier-side duty confirms the physician is an intended lawful recipient rather than a tolerated one: § 34-23-32(f) tells permit holders shipping to a new customer to assure themselves, by contacting the board’s office, that the recipient is a duly licensed doctor of medicine, dentistry or veterinary medicine, or holds a registered pharmacy permit. Alabama instructs the shipper to verify the doctor.

Administer vs dispenseHigh confidence

The statute draws the line inside the office-use section itself: under § 34-23-160(a) the product "shall be administered in the prescriber’s office and shall not be dispensed to the patient". For controlled stock the line is drawn again and favourably — rule 540-X-4-.05(4) provides that controlled substances consumed by or administered to patients while being treated in the physician’s office, clinic, hospital or other facility are not considered to be dispensed for the purposes of that rule, so pure in-office administration does not trigger the separate dispensing-physician registration.

Scheduled (controlled) stockHigh confidence

Yes, and it does not come from the board of pharmacy. The Alabama Controlled Substances Certificate is issued by the practitioner’s own licensing board — for physicians, the Board of Medical Examiners under Ala. Admin. Code ch. 540-X-4, $150 a year. The statute’s own plural gives it away: § 20-2-51(a) requires a registration issued by "the certifying boards". A separate registration is required at each principal place of business or professional practice under § 20-2-51(e).A compliance matrix that routes an Alabama physician’s controlled-substance registration to the board of pharmacy is wrong. Alabama is not alone in that — Oklahoma and West Virginia each route it away from the pharmacy board too, to different places — so the safe habit is to check the registrar in every state rather than to assume the pharmacy board holds it. It matters less than it looks for this vertical: compounded peptides and hormones are legend drugs rather than scheduled substances, so the certificate bites only if the shipment contains controlled substances.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• We did not read the governing text on this page from an official Alabama server. Two independent sources returned § 34-23-160 character for character, including its 2017 amendment history, and one of them was the legislature’s own service — but the official statutes site was not reached directly, and one official-server confirmation is cheap insurance before anything commercial is built on this page.
• Whether a pharmacy outside Alabama may invoke § 34-23-160 at all is genuinely open, and it is the most consequential unresolved question here. Office-use stock is by definition not for an identified Alabama patient, so whether the non-resident pharmacy permit is even triggered is an unanswered textual question. It decides whether an out-of-state pharmacy can serve Alabama prescribers under this section.
• "Inordinate amounts" in § 34-23-150(5) has no numeric threshold in the statute, in the board’s rules, or in any guidance we located. It is the only outer bound on the permission, and it cannot be measured in advance.
• The board has published no implementing rule, and a board that governs by statute alone often governs by newsletter. We swept no board newsletters, declaratory rulings, disciplinary orders or attorney-general opinions, and searched no case law; search engines were unavailable when this page was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.